Buy-side GenAI adoption hindered by broker research licensing restrictions despite 77% uptake, report reveals
“Buy-side research budgets are already under pressure, so it's understandable that they wouldn't welcome a new set of licensing accompanied by new costs and they are banking on a fear from the sell-side that being frozen out of an asset manager's LLM would be a very cold place to be in future,” Substantive Research chief executive tells The TRADE.